Are These Oversold Biotech Stocks Hiding a Lucrative Investment Opportunity?
Scholar Rock Holding Corporation is making strides in biotech with its promising therapy, Apitegromab, for spinal muscular atrophy, targeting regulatory submissions by early 2025. Despite a post-pandemic decline in mergers…